BRAF and metastatic melanoma: However, an additional MEK inhibitor that inhibits the MAPK pathway to BRAF inhibitors, trametinib, overcame BRAF inhibitor resistance, and demonstrated superiority over a BRAF inhibitor alone in phase III clinical trials in patients with BRAF mutant metastatic melanoma [64,65].